Edgar Filing: VITAL SIGNS INC

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q


(Mark one)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2006

	OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	FOR THE TRANSITION PERIOD FROM _______________ TO _______________

	COMMISSION FILE NUMBER: 0-18793



	VITAL SIGNS, INC.
	(Exact name of registrant as specified in its charter)


New Jersey		11-2279807
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

20 Campus Road
Totowa, New Jersey 07512
(Address of principal executive office, including zip code)

973-790-1330
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-12 of the Exchange Act.


o Large accelerated filer	x Accelerated filer	o Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).


	o Yes	x No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

At August 1, 2006 there were 13,216,088 shares of Common Stock, no par value, outstanding.

VITAL SIGNS, INC.

INDEX


		Page Number

	PART I.

Item 1.	Financial Statements	1
	Report of Independent Registered Public Accounting Firm	2
	Condensed Consolidated Balance Sheets as of June 30, 2006 (Unaudited) and September 30, 2005	3
	Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2006 and 2005 (Unaudited)	4
	Condensed Consolidated Statements of Income for the Nine Months Ended June 30, 2006 and 2005 (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2006 and 2005 (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7-11

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12-22

Item 3.	Quantitative and Qualitative Disclosure About Market Risks	22-23

Item 4.	Controls and Procedures	23

	PART II.

Item 1.	Legal Proceedings	24

Item 6.	Exhibits	25
	Signatures	26
	Exhibit 31.1
	Exhibit 31.2
	Exhibit 32.1
	Exhibit 32.2

PART I.

FINANCIAL INFORMATION

Item 1. Financial Statements

Certain information and footnote disclosures required under generally accepted accounting principles have been condensed or omitted from the following consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission. Vital Signs, Inc. (the “registrant”, the “Company”, “Vital Signs”, “we”, “us”, or “our”) believes that the disclosures are adequate to assure that the information presented is not misleading in any material respect. It is suggested that the following consolidated financial statements be read in conjunction with the year-end consolidated financial statements and notes thereto included in the registrant’s Annual Report on Form 10-K for the year ended September 30, 2005.

The results of operations for the interim periods presented herein are not necessarily indicative of the results to be expected for the entire fiscal year, or any other period.

In Management’s Discussion and Analysis of Results of Operations and Financial Condition, we refer to the Broselow-Luten System; Broselow; Infusable, Vivo and Limb-O, all of which are trademarks of Vital Signs, Inc.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors
Vital Signs, Inc.

We have reviewed the accompanying consolidated balance sheet of Vital Signs, Inc. and Subsidiaries as of June 30, 2006 and the related consolidated statements of income for the three months and nine months ended June 30, 2006 and 2005, and the consolidated statements of cash flows for the nine months ended June 30, 2006 and 2005. These interim financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the consolidated interim financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the consolidated financial statements referred to above for them to be in conformity with United States generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board, the consolidated balance sheet of Vital Signs, Inc. and Subsidiaries as of September 30, 2005 and the related consolidated statements of income, stockholders’ equity and cash flows for the year then ended (not presented herein); and in our report dated November 29, 2005 we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of September 30, 2005 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Effective October 1, 2005, Vital Signs, Inc. changed its method of accounting for stock options. The effects of these changes are disclosed in Note 6.

Goldstein Golub Kessler LLP

New York, New York
July 26, 2006

VITAL SIGNS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2006		September 30, 2005

	(In thousands of dollars)
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	119,293	$	81,767
Accounts receivable, less allowances for rebates and doubtful accounts of $8,276 and $7,821, respectively		33,873		34,417
Inventory		18,933		16,659
Prepaid expenses		3,563		2,917
Other current assets		1,388		1,016

Total Current Assets		177,050		136,776
Property, plant and equipment—net		31,237		29,938
Goodwill		79,272		77,167
Deferred income taxes		669		1,141
Other assets		9,245		8,680

Total Assets	$	297,473	$	253,702


LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	6,400	$	6,347
Accrued expenses		7,728		8,203
Accrued income taxes		537		2,671

Total Current Liabilities		14,665		17,221

Minority interest in subsidiary		4,439		3,775

Commitments and contingencies
Stockholders’ Equity:
Common stock—no par value; authorized 40,000,000 shares, issued and outstanding 13,216,088 and 12,593,579 shares, respectively		44,384		18,832
Accumulated other comprehensive income		3,005		2,012
Retained earnings		230,980		211,862

Stockholders’ equity		278,369		232,706

Total Liabilities and Stockholders’ Equity	$	297,473	$	253,702

(See Notes to Condensed Consolidated Financial Statements)

VITAL SIGNS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)


	For the Three Months Ended June 30,

	2006		2005

	(In thousands, except per share amounts)
Net Revenues:
Net sales	$	43,339	$	40,499
Service revenue		8,840		8,193

		52,179		48,692

Cost of goods sold and services performed:
Cost of goods sold		20,943		18,990
Cost of services performed		4,269		4,430

		25,212		23,420

Gross profit		26,967		25,272

Operating expenses:
Selling, general and administrative		13,356		13,211
Research and development		1,897		1,923
Restructuring expense		—		(136	)
Other expense (income)—net		42		(53	)

Total operating expenses		15,295		14,945

Operating Income		11,672		10,327

Other income
Interest income		779		601
Income from continuing operations before provision for income tax and minority interest in income of consolidated subsidiary		12,451		10,928
Provision for income taxes		4,241		3,846

Income from continuing operations before minority interest in income of consolidated subsidiary		8,210		7,082
Minority interest in income of consolidated subsidiary		292		191

Income from continuing operations		7,918		6,891
Discontinued Operations:
Income from operations of Vital Pharma, net of income tax provision of $14 and $68		26		127

Net income	$	7,944	$	7,018

Earnings per Common Share:
Basic
Income per share from continuing operations	$	0.60	$	0.55
Income per share from discontinued operations	$	0.00	$	0.01

Net earnings per share	$	0.60	$	0.56

Diluted
Income per share from continuing operations	$	0.60	$	0.54
Income per share from discontinued operations	$	0.00	$	0.01

Net earnings per share	$	0.60	$	0.55

Basic weighted average number of shares outstanding		13,159		12,627
Diluted weighted average number of shares outstanding		13,208		12,806
Dividends paid per share	$	0.09	$	0.07

(See Notes to Condensed Consolidated Financial Statements)

VITAL SIGNS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)


	For the Nine Months Ended June 30,

	2006		2005


	(In thousands, except per share amounts)
Net Revenues:
Net sales	$	124,288	$	116,916
Service revenue		26,914		24,502

		151,202		141,418

Cost of goods sold and services performed:
Cost of goods sold		59,900		56,530
Cost of services performed		14,071		13,493

		73,971		70,023

Gross profit		77,231		71,395

Operating expenses:
Selling, general and administrative		39,522		37,815
Research and development		5,294		5,589
Restructuring expense		—		224
Other expense (income) — net		149		(159	)

Total operating expenses		44,965		43,469

Operating Income		32,266		27,926

Other income (expense)
Interest income		2,009		1,234
Interest (expense)		—		(18	)

Total other income		2,009		1,216

Income from continuing operations before provision for income tax and minority interest in income of consolidated subsidiary		34,275		29,142
Provision for income taxes		11,580		10,242

Income from continuing operations before minority interest in income of consolidated subsidiary		22,695		18,900
Minority interest in income of consolidated subsidiary		664		419

Income from continuing operations		22,031		18,481
Discontinued Operations:
Income from operations of Vital Pharma, net of income tax provision of $23 and $51		41		95

Net income	$	22,072	$	18,576

Earnings per Common Share:
Basic
Income per share from continuing operations	$	1.71	$	1.46
Income per share from discontinued operations	$	0.00	$	0.01

Net earnings per share	$	1.71	$	1.47

Diluted
Income per share from continuing operations	$	1.70	$	1.45
Income per share from discontinued operations	$	0.00	$	0.00

Net earnings per share	$	1.70	$	1.45

Basic weighted average number of shares outstanding		12,881		12,619
Diluted weighted average number of shares outstanding		12,962		12,783
Dividends paid per share	$	0.23	$	0.20

(See Notes to Condensed Consolidated Financial Statements)

VITAL SIGNS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


	For the Nine Months Ended June 30,

	2006			2005

	(In thousands of dollars)
Cash Flows from Operating Activities:
Net income	$	22,072		$	18,576
(Income) loss from discontinued operations		(41	)		(95	)

Income from continuing operations		22,031			18,481
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations
Depreciation and amortization		3,658			4,406
Deferred income taxes		373			796
Tax benefit on stock options		—			506
Non-cash compensation expense		1,093			—
Minority interest in income of consolidated subsidiary		664			419
Changes in operating assets and liabilities:
Decrease in accounts receivable		789			911
(Increase) decrease in inventory		(2,094	)		277
Increase in prepaid expenses and other current assets		(976	)		(951	)
Increase in other assets		(296	)		(1,322	)
(Decrease) increase in accounts payable		(673	)		1,706
Decrease in accrued expenses		(636	)		(433	)
(Decrease) increase in accrued income taxes		(2,035	)		126
Increase in other liabilities		—			177

Net cash provided by continuing operations		21,898			25,099
Net cash provided by (used in) discontinued operations		41			95

Net cash provided by operating activities		21,939			25,194

Cash flows from investing activities:
Acquisition of Baxter disposable airways product line		—			(9,965	)
Acquisition of assets of Futall AB		(2,276	)		—
Acquisition of property, plant and equipment		(4,010	)		(2,126	)
Capitalized software costs		(430	)		(1,673	)
Capitalized patent costs		(223	)		(107	)

Net cash used in investing activities		(6,939	)		(13,871	)

Cash flows from financing activities:
Net proceeds from sale of common stock		18,575			—
Dividends paid		(2,956	)		(2,529	)
Tax benefit on stock options		1,989			—
Proceeds from exercise of stock options		4,113			2,996
Purchase of common stock		(217	)		(7,883	)

Net cash provided by (used in) financing activities		21,504			(7,416	)
Effect of foreign currency translation		1,022			(1,475	)

Net increase in cash and cash equivalents		37,526			2,432
Cash and cash equivalents at beginning of period		81,767			76,468

Cash and cash equivalents at end of period	$	119,293		$	78,900

Supplemental disclosures of cash flow information:
Cash paid during the Nine months for:
Interest	$	—		$	19
Income taxes	$	9,516		$	8,347
Supplemental schedule of non-cash financing activities:

Fair value of common stock received as payment for exercise of stock options	$	1,586		$	—

(See Notes to Condensed Consolidated Financial Statements)

VITAL SIGNS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. The consolidated balance sheet as of June 30, 2006, the consolidated statements of income for the three months and nine months ended June 30, 2006 and 2005, and the consolidated statements of cash flows for the nine months ended June 30, 2006 and 2005, have been prepared by Vital Signs, Inc. (the “registrant”, the “Company”, “Vital Signs”, “we”, “us”, or “our”) and are unaudited. The September 30, 2005 consolidated balance sheet has been derived from the audited financial statements for the year ended September 30, 2005. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position at June 30, 2006 and the results of operations for the three months and nine months ended June 30, 2006 and 2005, and the cash flows for the nine months ended June 30, 2006 and 2005, have been made.

2. See the Company’s Annual Report on Form 10-K for the year ended September 30, 2005 (the “Form 10-K”) for additional disclosures relating to the Company’s consolidated financial statements.

3. At June 30, 2006, the Company’s inventory was comprised of raw materials of $12,613,000 and finished goods of $6,320,000. At September 30, 2005, the Company’s inventory was comprised of raw materials of $11,142,000 and finished goods of $5,517,000.

4. The Company has aggregated its business units into four reportable segments, Anesthesia, Respiratory/Critical Care, Sleep and Pharmaceutical Technology Services. There are no material intersegment sales. Anesthesia and Respiratory/Critical Care share certain manufacturing, sales and administration costs; therefore the operating profit, total assets, and capital expenditures are not specifically identifiable. However the Company has allocated these shared costs on a net sales basis to arrive at operating profit for the anesthesia and respiratory/critical care segments. Total assets and capital expenditures for anesthesia and respiratory/critical care have also been allocated on a net sales basis. Management evaluates performance on the basis of the gross profits and operating results of the four business segments. Summarized financial information concerning the Company’s reportable segments is shown in the following table:

VITAL SIGNS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)


(dollars in thousands)	Anesthesia			Respiratory Critical Care			Sleep			Pharmaceutical Technology Services			Consolidated

For the three months ended June 30:
2006
Net revenues	$	25,128		$	11,438		$	11,973		$	3,640		$	52,179
Gross profit		12,995			5,902			6,756			1,314			26,967
Gross profit percentage		51.7	%		51.6	%		56.4	%		36.1	%		51.7	%
Operating income		6,506			2,961			1,963			242			11,672
2005
Net revenues	$	24,038		$	10,515		$	10,331		$	3,808		$	48,692
Gross profit		13,158			5,615			5,097			1,402			25,272
Gross profit percentage		54.7	%		53.4	%		49.3	%		36.8	%		51.9	%
Operating income		6,736			2,946			543			102			10,327

For the nine months ended June 30:
2006
Net revenues	$	72,173		$	32,943		$	33,780		$	12,306		$	151,202
Gross profit		37,390			17,328			18,214			4,299			77,231
Gross profit percentage		51.8	%		52.6	%		53.9	%		34.9	%		51.1.	%
Operating income		18,299			8,353			4,588			1,026			32,266
Total assets		162,112			73,995			41,851			19,515			297,473
Capital expenditures		2,293			1,047			1,087			236			4,663
2005
Net revenues	$	65,489		$	31,714		$	31,862		$	12,353		$	141,418
Gross profit		35,242			16,808			14,698			4,647			71,395
Gross profit percentage		53.8	%		53.0	%		46.1	%		37.6	%		50.5	%
Operating income		17,997			8,716			483			730			27,926
Total assets		130,145			63,025			34,710			18,658			246,538
Capital expenditures		2,607			653			587			59			3,906

5. Other comprehensive income for the three months and nine months ended June 30, 2006 and 2005 consisted of:


	Three Months Ended June 30,					Nine months ended June 30,

(in thousands)	2006		2005			2006		2005

Net income	$	7,944	$	7,018		$	22,072	$	18,576
Foreign currency translation		1,105		(2,187	)		993		(1,564	)

Comprehensive income	$	9,049	$	4,831		$	23,065	$	17,012

6. Effective October 1, 2005, the Company began recording compensation expense associated with stock options in accordance with SFAS No. 123R, “Share-Based Payment”. Prior to October 1, 2005, the Company accounted for stock-based compensation related to stock options under the recognition and measurement principles of Accounting Principles Board Opinion No. 25; therefore, the Company measured compensation expense for its stock option plans using the intrinsic value method, that is, as the excess, if any, of the fair market value of the Company’s stock at the grant date over the amount required to be paid to acquire the stock, and provided the disclosures required by SFAS Nos. 123 and 148. The Company has adopted the modified prospective transition method provided under SFAS No. 123R, and as a result, has not retroactively adjusted results from prior periods. Under this transition method, compensation expense associated with stock options recognized in the first, second and third quarters of fiscal year 2006 includes: 1) expense related to the remaining unvested portion of all stock option awards granted prior to October 1, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123; and 2) expense related to all stock option awards granted subsequent to October 1, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123R.

As a result of the adoption of SFAS No. 123R, the Company’s net income for the three month and nine month periods ended June 30, 2006 includes $329,000 and $1,093,000, respectively, of compensation expense and related reductions in income tax expenses of $114,000 and $370,000, respectively. The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of both selling, general and administrative and research and development expenses. Prior to the Company’s adoption of SFAS No. 123R, the Company presented tax benefits resulting from the exercise of stock options as cash flows from operating activities on the Company’s consolidated statements of cash flows. SFAS No. 123R requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities.

At June 30, 2006, the Company had two stock option plans. The Vital Signs 2003 Investment Plan, provides for the grant of options to employees, officers and directors to purchase the Company’s common stock. The 2003 Investment Plan is a renewal of the Company’s 1994 Investment Plan, which expired in January 2004. One million shares of the Company’s common stock have been authorized for share purchase and option grants. Options may be granted at prices not less than fair value at the date of grant. The options have a ten-year life. Options generally vest after a two-year period. Shares purchased by persons who are not executive officers or directors may be financed through the Company. The 2002 Stock Incentive Plan provides for the grant of options to employees, officers, directors and consultants to purchase a maximum of one million shares. Although the 2002 Stock Incentive Plan allows for the grants of stock options to consultants, to date no options have been granted to consultants under that plan. Options may be granted at prices not less than fair value at the date of grant. The options have a ten-year life. Options generally vest ratably over a five-year period commencing on the first anniversary of the grant with respect to options granted to employees under the 2002 Stock Incentive Plan. The vesting period for options granted to directors under the 2002 Stock Incentive Plan varies depending on the basis for the grant. The 2002 Stock Incentive Plan expires on May 31, 2012.

For stock option grants prior to October 1, 2005, the estimated fair value of each option award granted was determined on the date of grant using the Black-Scholes option valuation model. For stock option grants on and after October 1, 2005, the estimated fair value of each option award granted was determined on the date of grant using a lattice based option valuation model. The following weighted-average assumptions were used for option grants during the three month and nine month periods ended June 30, 2006 and 2005:


	Three Months Ended June 30,						Nine Months Ended June 30,

	2006			2005			2006			2005

Risk-free interest rate		5.22	%		5.00	%		4.50	%		5.00	%

Expected volatility of common stock		34.75	%		33.00	%		34.75	%		33.00	%

Dividend yield		0.65	%		0.70	%		0.65	%		0.70	%

Expected option term		3.3 -6.4 years			5.0 -10.0 years			3.4 -6.4 years			5.0 - 10.0 years

The risk-free interest rate for the nine months ended June 30, 2006 is based on the 5 year U.S. Treasury bill rate on the day of the grant. There were 5,000 options granted during the three months ended June 30, 2006. For the three months and nine months ended June 30, 2005 the rate is based on the implied yield on a U.S. Treasury bond with constant maturities with a remaining term equal to the expected term of the option. The expected volatility is based on the historical volatility of the Company’s stock. For options granted during the nine months ended June 30, 2006, the expected volatility computation is based on the average of the volatility over the most recent four year period. For options granted during the three months and nine months ended June 30, 2005, the expected volatility computation is based on the volatility over a 1.67 year period prior to the date of grant of such options.

A summary of the status of the Company’s stock option plans as of June 30, 2006 and of changes in options outstanding under the plans during the nine months ended June 30, 2006 is as follows:


	Number of Shares			Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value


Options outstanding at September 30, 2005		582,211		$	29.32

Options granted		42,750		$	44.33

Options exercised		(224,821	)	$	25.35

Options forfeited or expired		(24,151	)	$	38.33


Options outstanding at June 30, 2006		375,989		$	32.82		8.78	$	6,283,219


Options vested and exercisable at June 30, 2006		219,391		$	28.87		6.18	$	4,533,378

The weighted-average fair value of each option granted during the nine month periods ended June 30, 2006 and 2005, estimated as of the grant date using a lattice based option valuation model (2006) and the Black-Scholes option valuation model (2005), was $12.32 per option and $20.56 per option, respectively.

A summary of the status of the Company’s nonvested shares as of September 30, 2005, and changes during the nine months ended June 30, 2006 is presented below:


	Number of Shares		Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)


Nonvested shares at September 30, 2005	206,146		$	36.05	8.18

Options granted	42,750		$	44.33	9.21

Options vested	(72,586	)	$	35.36	8.04

Options forfeited or expired	(19,712	)	$	38.25	8.66


Nonvested shares at June 30, 2006	156,598		$	38.36	8.46

As of June 30, 2006, there was $2.1 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 3.75 years.

For stock options granted prior to the adoption of SFAS No. 123R, the following table illustrates the pro forma effect on net income and earnings per common share as if the Company had applied the fair value recognition provisions of SFAS No. 123, as amended by SFAS No. 148, to apply the accounting rules under APB Opinion No.25 and related interpretations in accounting for its stock options in determining stock-based compensation for awards under the plan:


(in thousands, except share amounts)	Three Month period ended June 30, 2005		Nine Month Period ended June 30, 2005

Net income —as reported	$	7,018	$	18,576
Stock compensation expense		403		884
Net income —Pro forma	$	6,615	$	17,692
Basic net income per common share—as reported	$	0.56	$	1.47
Diluted net income per common share—as reported	$	0.55	$	1.45
Basic net income per common share—Pro forma	$	0.52	$	1.40
Diluted net income per common share—Pro forma	$	0.52	$	1.38

Cash received from stock option exercises for the nine months ended June 30, 2006 and 2005 was $4,113,000 and $2,996,000, respectively. The income tax benefits from stock option exercises totaled $1,989,000 and $506,000 for the nine months ended June 30, 2006 and 2005, respectively.

7. In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109 (“FIN 48”), which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions. A tax benefit from an uncertain position may be recognized only if it is “more likely than not” that the position is sustainable based on its technical merits. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company does not expect that FIN 48 will have a material effect on its consolidated financial condition or results of operations.

The Company does not believe that any recently issued but not yet effective accounting standards will have a material effect on the Company’s financial position or results of operations.

8. Included in the Company’s revenues in the Anesthesia and Respiratory/ Critical Care segments, are sales made to distributors. For the three month and nine month periods ended June 30, 2006, these sales accounted for approximately 27.6% and 27.7%, respectively, of the net sales of the Company. Price rebates are available to the distributor based upon the difference between the established price (distributor list) and the lower price that the distributor is entitled to after selling the goods to the end-user hospital (distributor final). The Company estimates

and records the applicable rebates that have been or are expected to be granted or made for products sold during the period. Rebates are recorded as a reduction to gross sales in the same period as the related sales are recorded.

9. On March 2, 2005 the Company acquired a disposable airway management device business from a subsidiary of Baxter International, Inc. to improve the Company’s market share in the anesthesia segment. The purchase price for the acquisition, including related costs, was approximately $10.1 million. The transaction included the acquisition of certain manufacturing assets related to the business valued at approximately $1,259,000, as well as inventory including anesthesia circuits, face masks, heat and moisture exchanger filters and other associated anesthesia components valued at approximately $1,128,000. The excess of the purchase price over the fair value of the net assets acquired, which has been allocated to goodwill, was approximately $7,700,000, and is included in the anesthesia segment. Goodwill was recognized in accordance with Statement of Financial Standards No. 142 (“Goodwill and Other Intangible Assets”).

The following summary, pro forma, unaudited data of the Company reflects the acquisition of the Baxter disposable airway management device business as if the acquisition had occurred on October 1, 2004.



	Three Month Period Ended June 30,		Nine Month Period Ended June 30,

(in thousands, except per share amounts)	2005		2005

Net sales	$	52,110	$	146,499
Net income		6,828		19,578
Basic net income per common share	$	.55	$	1.55
Diluted net income per common share	$	.54	$	1.53

Such pro forma data is not necessarily indicative of future results of operations.

On November 14, 2005 the Company acquired the assets of Futall AB, a Swedish company holding the rights to certain carbon dioxide detection technology of the type used by the Company in its C-CO2^TMproduct. The assets consisted of intellectual property rights including patents and trade secrets, manufacturing equipment, and office equipment. The purchase price is comprised of (i) an initial payment of $2,000,000 and, (ii) a royalty on future sales. Royalties of $28,000 have been earned by the selling shareholders of Futall and charged to operations. The transaction includes the acquisition of certain patents valued at approximately $155,000. The excess of the purchase price over the fair value of the net assets acquired, which has been preliminarily allocated to goodwill and may be subject to adjustment, was approximately $2,105,000, and is included in the anesthesia and respiratory/critical care segments. Goodwill was recognized in accordance with Statement of Financial Standards No. 142 (“Goodwill and Other Intangible Assets”). Since the acquisition of Futall AB, and its related operations, are immaterial, no pro forma information has been presented.

10. In accordance with SFAS No. 142, Goodwill and intangible assets that have indefinite useful lives are no longer amortized but rather are to be tested for impairment annually or more frequently if impairment indicators arise. The Company completed this impairment test during the three-month period ended March 31, 2006 and found no impairment. If the Company is required to record impairment charges in the future, it could have an adverse impact on its results of operations and financial condition. Goodwill increased during the time periods presented as follows:


	For the Nine month periods ended June 30,

(dollars in thousands)	2006		2005

Beginning balance	$	77,167	$	69,506
Goodwill acquired during the year		2,105		7,700

Ending balance	$	79,272	$	77,206

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our consolidated financial statements and notes to those consolidated financial statements, included elsewhere in this report.

Forward Looking Statements

This report contains forward-looking statements (as such term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934) that are based on our management’s beliefs and assumptions and on information currently available to us. These statements may be found throughout this report, particularly under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. These sections contain discussions of some of the factors that could cause actual results to differ materially from the results projected in our forward-looking statements. When used in this report, the words or phrases “will likely result,” “expects,” “intends,” “will continue,” “is anticipated,” “estimates,” “projects,” “management believes,” “we believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act and the Securities Act. Forward-looking statements include plans and objectives of management for future operations. These forward-looking statements involve risks and uncertainties and are based on assumptions that may not be realized. Actual results and outcomes may differ materially from those discussed or anticipated.

All forward-looking statements are subject to known and unknown risks and uncertainties, including those discussed in Item 1A of our Annual Report on Form 10-K for the year ended September 30, 2005, that could cause actual results to differ materially from historical results and those presently anticipated or projected. No forward-looking statement is a guarantee of future performance. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. You should read our cautionary statements as being applicable to all related forward-looking statements whenever they appear in:


	•	this report and materials referred to in this report; and

	•	our press releases.

Overview

We are a leading designer, manufacturer and marketer of airway management products for the anesthesia, respiratory/critical care and sleep disorder markets. We sell our products in over 70 countries worldwide. We offer one of the broadest single-patient use anesthesia and respiratory/critical care product lines in the industry and have developed numerous innovative products which are now considered industry standards. In addition, we sell therapeutic products for patients suffering from sleep disorders and provide sleep disorder diagnoses at sleep centers and laboratories that we operate. We also deliver technology services to companies regulated by the United States Food and Drug Administration, or FDA.

Anesthesia

Our single-patient use anesthesia products and systems are designed to deliver oxygen and anesthesia from a gas source, such as an anesthesia machine, to a patient’s pulmonary system, remove anesthetic gases, oxygen and carbon dioxide from a patient and link a patient with various monitors. Our principal anesthesia products consist of face masks, breathing circuits and general anesthesia products. We also include within this segment the products sold by our Thomas Medical Products subsidiary. Thomas Medical is an original equipment manufacturer that primarily manufactures vascular access products for sale to other health care product providers to be used in their products or kits or as a finished product.

Revenues in our anesthesia segment are driven primarily by the extent to which our hospital customers perform general surgeries and by the aging of the populations in the geographical markets that we serve. In addition, because most of our anesthesia products are single use products, we benefit when hospitals undertake programs to reduce the frequency of infections, known as nosocomial infections, which originate or occur within their settings. Revenues in

this segment are negatively impacted by the trend among hospitals to allow group purchasing organizations to negotiate long-term contracts with medical device manufacturers on their behalf. Expenses in our anesthesia segment are driven primarily by the cost of raw materials, labor costs and freight expenses.

In March 2005, we acquired the disposable airway management device business from a subsidiary of Baxter International Inc. for approximately $10.1 million, including related transaction costs. This acquisition was structured as an asset purchase pursuant to which we acquired certain manufacturing assets related to the disposable airway management device business valued at approximately $1.3 million, and inventory, including anesthesia circuits, face masks, heat and moisture exchanger filters and other associated anesthesia components valued at approximately $1.2 million. The excess of the purchase price over the fair value of the net assets acquired, which has been allocated to goodwill, was approximately $7.7 million.

Respiratory/critical care

Our primary respiratory/critical care products are arterial blood gas, or ABG, syringes and kits, manual resuscitators and blood pressure cuffs. Our respiratory/critical care segment responds to the growing needs of hospitals to provide respiratory relief and emergency care. We believe that in recent years there has been an increasing incidence of respiratory illnesses, such as asthma and emphysema, due in part to an increasingly susceptible aging population, environmental pollution, smoking-related illnesses and communicable diseases with significant respiratory impact, such as tuberculosis, HIV and influenza. These trends, together with concerns regarding the spread of nosocomial infections, drive our sales of respiratory products. As in our anesthesia segment, revenues in this segment have been negatively impacted by the emergence of group purchasing organizations and expenses in this segment are driven principally by raw material costs, labor costs and freight expenses.

Sleep Disorders

We serve the sleep disorder market as both a provider of diagnostic services and a manufacturer of therapeutic products focused on sleep disorders. Through our Sleep Services of America, or SSA, subsidiary, we provide sleep diagnostic testing services in the United States in free standing laboratories and centers and, through contracts with hospitals, in hospital facilities, for patients suspected of suffering from obstructive sleep apnea. As of June 30, 2006, we managed 52 sleep laboratories and centers. We have focused our efforts on laboratories and centers affiliated with hospitals, such as Johns Hopkins and the University of Maryland. Our diagnostic services business is driven by the growing awareness of the existence and significant consequences of obstructive sleep apnea. Our principal expense in our sleep diagnostic services business is the cost of employing the technicians who operate our sleep laboratories and centers.

Our Breas Medical AB, or Breas, subsidiary is a European manufacturer of personal ventilators for obstructive sleep apnea and long term ventilation. Our sleep disorder products deliver airflow to patients undergoing therapy for the treatment of obstructive sleep apnea with the objective of increasing patient comfort and acceptance of the treatment. Our sleep disorder products employ continuous positive airway pressure, or CPAP, which is a common method for treating obstructive sleep apnea. We have manufactured and distributed CPAP systems for more than a decade. Our sales of sleep disorder and other personal ventilation products have been made principally in international markets. These sales depend principally on the prevalence of sleep disorders and the acceptance by patients and care-givers in developed markets of treatment modalities for obstructive sleep apnea. Like our anesthesia and respiratory/critical care businesses, our Breas subsidiary faces the challenge of controlling raw material, labor and freight costs. To date, we have had only limited sales of our sleep disorder products in the United States due in part to the need to obtain regulatory clearance and in part to the dominance by our competitors in selling to home supply dealers. Our United States strategy is to sell these products primarily through our sleep centers, subject to applicable legal requirements.

Pharmaceutical technology services

We deliver technology services to FDA regulated companies primarily in the pharmaceutical sector. In addition, we also provide services to medical device, diagnostic and biotechnology companies. We advise clients by helping them establish and monitor processes designed to satisfy their regulatory requirements set forth by the FDA and have begun to sell dedicated compliance software to our clients. We entered the pharmaceutical regulatory services market in 1996 and expanded into computer system compliance though our acquisition in 2002 of Stelex Inc. This segment benefits from regulatory efforts to systemize compliance by the regulated community and by our clients’ efforts to control costs through the outsourcing of compliance functions. Our principal costs in this segment

are our labor costs. We also incur technology-related expenses as part of our development of compliance software standards.

Net revenues

Net revenues consist of sales of our anesthesia, respiratory/critical care and sleep disorder and personal ventilation products and revenues from our sleep disorder diagnostic services and pharmaceutical technology services. The amount and percentage of our net revenue derived from each of our business segments were as follows during the periods indicated:


	Three months ended June 30, 2006					Three months ended June 30, 2005

(dollars in thousands)	Net revenue		Percent of total revenue			Net revenue		Percent of total revenue


Anesthesia	$	25,128		48.2	%	$	24,038		49.4	%

Respiratory/critical care		11,438		21.9	%		10,515		21.6	%

Sleep disorder and personal ventilation		11,973		22.9	%		10,331		21.2	%

Pharmaceutical technology services		3,640		7.0	%		3,808		7.8	%


Total	$	52,179		100.0	%	$	48,692		100.0	%


	Nine months ended June 30, 2006					Nine months ended June 30, 2005

(dollars in thousands)	Net revenue		Percent of total revenue			Net revenue		Percent of total revenue


Anesthesia	$	72,173		47.7	%	$	65,489		46.3	%

Respiratory/critical care		32,943		21.8	%		31,714		22.4	%

Sleep disorder and personal ventilation		33,780		22.4	%		31,862		22.5	%

Pharmaceutical technology services		12,306		8.1	%		12,353		8.8	%


Total	$	151,202		100.0	%	$	141,418		100.0	%

For product sales, revenue net of allowances for rebates and sales allowances, is recognized when title passes upon shipment to the customer (except for certain domestic distributors where revenue, net of calculated allowances for rebates and sales allowances, is recognized upon delivery of goods to the customer). The Company estimates and records the applicable rebates that have been or are expected to be granted (and records an allowance for rebates) for all revenue recognized for products sold during the period.

Gross revenues associated with our anesthesia and respiratory/critical care products are reduced by the amount of rebates due on sales to distributors. Sales to distributors represented 27.6% and 28.2% of our net sales during the

three months ended June 30, 2006, and 2005, respectively, and 27.7% and 25.8% of our net sales during the nine months ended June 30, 2006, and 2005, respectively

We have provided a reconciliation of gross to net product sales, as well as a comparison with service revenues, below:


	Three Months Ended June 30,						Nine months ended June 30,

	2006			2005			2006			2005

Gross sales	$	61,054		$	55,801		$	175,065		$	160,482
Rebates		(16,629	)		(14,293	)		(47,466	)		(40,769	)
Other deductions		(1,086	)		(1,009	)		(3,311	)		(2,797	)

Net sales		43,339			40,499			124,288			116,916
Service revenues		8,840			8,193			26,914			24,502

Total net revenues	$	52,179		$	48,692		$	151,202		$	141,418

Other deductions consist of discounts, returns and allowances for credits.

For service revenue in the sleep disorder and pharmaceutical technology services segments, revenue is recognized when the service is performed.

Research and development

The focus of our research and development efforts, and the amount of such expenses that we incur, vary from year to year and quarter to quarter based on the specific needs of our business. For each of the three month periods ended June 30, 2006 and 2005, we incurred $1.9 million of research and development expenses. For the nine months ended June 30, 2006 and 2005, we incurred $5.3 million and $5.6 million of research and development expenses, respectively.

International sales

Our products are sold in over 70 countries worldwide. The table below sets forth our international sales, by segment, for the periods presented:


	Three months ended June 30, 2006					Three months ended June 30, 2005

	Net revenue		Percent of total revenue			Net revenue		Percent of total revenue

	(dollars in thousands)
Anesthesia	$	2,593		5.0	%	$	2,276		4.7	%
Respiratory/critical care		3,372		6.5			3,653		7.5
Sleep disorder		6,773		13.0			5,946		12.2

Total	$	12,738		24.4	%	$	11,875		24.4	%


	Nine months ended June 30, 2006					Nine months ended June 30, 2005

	Net revenue		Percent of total revenue			Net revenue		Percent of total revenue

	(dollars in thousands)
Anesthesia	$	6,849		4.5	%	$	6,206		4.4	%
Respiratory/critical care		9,747		6.5			10,286		7.3
Sleep disorder		19,174		12.7			19,715		13.9

Total	$	35,770		23.7	%	$	36,207		25.6	%

During the past year, we have transitioned from our three year alliance with Teleflex (Rusch) to distributors in each of the ten countries covered under the agreement, which we previously entered into with Teleflex. Even with this transition, international sales in the Anesthesia and Respiratory/Critical Care segments have increased by $36,000 (0.6%) and $104,000 (0.6%) for the three month and nine month periods ended June 30, 2006, respectively, over the comparable period in last fiscal year.

Foreign exchange risks

Our international business exposes us to foreign exchange risks, particularly with respect to our sleep disorder segment and, more particularly, with respect to international sales of our sleep disorder and personal ventilation products by our Breas subsidiary. Sales of such products by our Breas subsidiary are translated from Swedish Kroner to United States Dollars.

Results of operations

The following table sets forth, for the periods indicated, certain statement of income data as a percentage of our net revenue.

Consolidated statement of income data (as a percentage of sales):


	Three Months ended June 30,						Nine Months ended June 30,

	2006			2005			2006			2005

Net revenue		100.0	%		100.0	%		100.0	%		100.0	%
Cost of goods sold		48.3			48.1			48.9			49.5
Gross profit:
Anesthesia		51.7			54.7			51.8			53.8
Respiratory/critical care		51.6			53.4			52.6			53.0
Sleep disorder		56.4			49.3			53.9			46.1
Pharmaceutical technology services		36.1			36.8			34.9			37.6
Total		51.7			51.9			51.1			50.5
Operating expenses:
Selling, general and administrative		25.6			27.1			26.1			26.7
Research and development		3.6			3.9			3.5			4.0
Restructuring and impairment		—			(0.3	)		—			0.2
Other expense, net		0.1			(0.1	)		0.1			(0.1	)
Total operating expenses		29.3			30.7			29.7			30.7
Interest income, net		(1.5	)		(1.2	)		(1.3	)		(0.9	)
Provision for income taxes		8.1			7.9			7.7			7.2
Income from continuing operations		15.2			14.2			14.6			13.1
Net income		15.2			14.4			14.6			13.1

Comparison of Results for the Three-Months Ended June 30, 2006 to the Three-Months Ended June 30, 2005.

Net Revenue. Net revenues for the three months ended June 30, 2006 increased by 7.2% (an increase of 7.3% excluding the unfavorable effect of foreign exchange) to $52.2 million as compared to $48.7 million in the comparable period last year. Of our total revenues for the three months ended June 30, 2006, $39.5 million, or 75.6%, were derived from domestic sales and $12.7 million, or 24.4%, were derived from international sales. Domestic revenues increased by 7.1%, from $36.8 million for the third quarter of fiscal 2005 to $39.5 million for the third quarter of fiscal 2006. International sales increased by 7.3%, from $11.9 million for the third quarter of fiscal 2005 to $12.7 million for the third quarter of fiscal 2006. The international sales increase would have been an 8.0% increase were it not for foreign exchange rates. During the past year, we have transitioned from our three year alliance with Teleflex (Rusch) to distributors in each of the ten countries covered under the agreement, which we previously entered into with Teleflex. Despite this transition, international sales in the Anesthesia and Respiratory/Critical Care segments have increased by 0.6% for the three month period ended June 30, 2006 over the comparable period in last fiscal year. The references in this Quarterly Report to international sales adjusted to exclude foreign exchange rates may represent “Non-GAAP Financial Measures”. We believe that these references are helpful in describing the underlying operations of the Company.

The following are the net revenues by business segment for the three months ended June 30, 2006 compared to the three months ended June 30, 2005:

Net revenue by business segment



Three months ended June 30, (Dollars in thousands)		2006		2005	Percent change


Anesthesia	$	25,128	$	24,038	4.5	%
Respiratory/critical care		11,438		10,515	8.8	%
Sleep disorder		11,973		10,331	15.9	%
Pharmaceutical technology services		3,640		3,808	(4.4	)%

Total	$	52,179	$	48,692	7.2	%

Anesthesia. Sales of anesthesia products increased 4.5% from $24.0 million for the three months ended June 30, 2005 to $25.1 million for the three months ended June 30, 2006. Domestic sales of anesthesia products increased 3.6%, from $21.8 million for the three months ended June 30, 2005 to $22.5 million for the three months ended June 30, 2006. International sales of anesthesia products increased 13.9%, from $2.3 million for the three months ended June 30, 2005 to $2.6 million for the three months ended June 30, 2006.

Respiratory/critical care. Sales of respiratory/critical care products increased 8.8%, from $10.5 million for the three months ended June 30, 2005 to $11.4 million for the three months ended June 30, 2006, resulting primarily from an increase in sales of our blood pressure cuffs and resuscitator product lines, offsetting a decline in sales of our ABG product line. Domestic sales of respiratory/critical care products increased by 17.5%, from $6.9 million for the three months ended June 30, 2005 to $8.1 million for the three months ended June 30, 2006. International sales of respiratory/critical care products decreased by 7.7%, from $3.7 million for the three months ended June 30, 2005 to $3.4 million for the three months ended June 30, 2006.

Sleep Disorder. Net revenues in our sleep disorder segment increased 15.9% (an increase of 16.8% excluding foreign exchange) from $10.3 million for the three months ended June 30, 2005 to $12.0 million for the three months ended June 30, 2006. At Breas, our European manufacturer of personal ventilators and CPAP devices, revenue increased 13.9%. The net revenues at Sleep Services of America (SSA), our domestic sleep disorder diagnostic business, increased 18.6%, from $4.4 million to $5.2 million, resulting primarily from improved utilization at existing labs. The same center revenue growth was 16.2%

Pharmaceutical technology services. Service revenues in our pharmaceutical technology services segment for the three months ended June 30, 2006 decreased by 4.4% from $3.8 million to $3.6 million.

Gross profit

We have set forth below the dollar amount of our gross profits and our gross profit margins for each of our four segments:



Three months ended June 30, (Dollars in thousands)	2006					2005

	Gross profit		Gross profit margin			Gross profit		Gross profit margin
Anesthesia	$	12,995		51.7	%	$	13,158		54.7	%
Respiratory/critical care		5,902		51.6			5,615		53.4
Sleep disorder		6,756		56.4			5,097		49.3
Pharmaceutical technology services		1,314		36.1			1,402		36.8

Total	$	26,967		51.7	%	$	25,272		51.9	%

The gross profit dollar and margin decline in the anesthesia segment was primarily due to the increase in the cost of plastic resins and in-bound freight resulting from higher oil costs experienced nationwide and the impact of an increase in the sales of lower margin products sold by Thomas Medical Products. The gross profit margin decline in the respiratory/critical care segment was primarily due to the increase in the cost of plastic resins and in-bound freight resulting from higher oil costs experienced nationwide.

The gross profit dollar increase in our sleep disorder segment resulted from improved utilization at our sleep diagnostic centers as well a higher gross profit margin on new Breas products. The gross profit margin in sleep disorder diagnostic services increased from 53.8% in the third quarter of fiscal 2005 to 62.6% in the third quarter of fiscal 2006 resulting primarily from revenue growth while maintaining costs at historical levels. The gross profit margin at Breas increased from 46.0% in the third quarter of fiscal 2005 to 51.7% in the third quarter of fiscal 2006 reflecting the sale of the new Breas products at a higher profit margin.

The gross profit dollar and margin decrease in our pharmaceutical technology services segment during the three months ended June 30, 2006 corresponds to the revenue decline described above.

Operating Expenses

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased 1.1%, from $13.2 million for the three months ended June 30, 2005 to $13.4 million for the three months ended June 30,

2006. The increase consists primarily of increased freight expense of $366,000 relating to our sales volume increase and the fuel surcharges imposed by freight carriers, $242,000 for non-cash option compensation expense resulting from the implementation of FASB 123R, increased accounting fees of $221,000 and increased legal fees of $233,000.These increases were partially offset by reduced compensation costs of $451,000, foreign exchange of $215,000 and savings in health insurance of $282,000. For information regarding our implementation of FASB 123R, see Note 6 of Notes to Consolidated Financial Statements.

Research and Development Expenses. Research and development expenses remained at approximately $1.9 million for the three months ended June 30, 2005 and for the three months ended June 30, 2006.

Restructuring Expense. Restructuring expense for the three months ended June 30, 2005 consisted of $136,000 reversal of accrued costs related to the final shutdown of our California manufacturing plant that occurred in February 2005.

Other (Income) Expense—Net. Other (income) expense, net, included in operating expenses consisted of $42,000 of net expense for the three months ended June 30, 2006 and $53,000 of net gain for the three months ended June 30, 2005. The net expense for the three months ended June 30, 2006 consisted primarily of donation expense. The net gain for the three months ended June 30, 2005 consisted primarily of realized foreign exchange gains at our Breas subsidiary.

Interest Income and Expense. Interest income increased $0.2 million from $0.6 million for the three months ended June 30, 2005 to $0.8 million during the three months ended June 30, 2006, resulting from an increase in available cash and cash equivalents attributable in part to our February 2006 public offering and increased interest rates.

Provision for Income Taxes. The provision for income tax expense for the three months ended June 30, 2006 and 2005 was $4.2 million and $3.8 million, respectively, reflecting effective tax rates of 34.1% and 35.2% for these periods, respectively. The 2006 tax rate reflected our ability to utilize a tax deduction available to United States manufacturers resulting from the American Jobs Creation Act of 2005 and the utilization of a tax advantaged investment portfolio to minimize tax on interest income.

Discontinued Operations. The net gain from discontinued operations was $26,000 (consisting of interest income generated from a note receivable) and $127,000 for the three months ended June 30, 2006 and 2005, respectively.

Comparison of Results for the Nine-Months Ended June 30, 2006 to the Nine-Months Ended June 30, 2005.

Net Revenue. Net revenues for the nine months ended June 30, 2005 increased by 6.9% (an increase of 8.2% excluding the unfavorable effect of foreign exchange) to $151.2 million as compared to $141.4 million in the comparable period last year. Of our total revenues, $115.4 million, or 76.3%, were derived from domestic sales and $35.8 million, or 23.7%, were derived from international sales. Domestic revenues increased by 9.7%, from $105.2 million for the nine months ended June 30, 2005 to $115.4 million for the nine months ended June 30, 2006. International sales decreased by 1.2%, from $36.2 million for the nine months ended June 30, 2005 to $35.8 million for the nine months ended June 30, 2006. Excluding the effects of foreign exchange, the international sales would have increased 3.6%. During the past year, we have transitioned from our three year alliance with Teleflex (Rusch) to distributors in each of the ten countries covered under the agreement, which we previously entered into with Teleflex. Despite this transition, international sales in the Anesthesia and Respiratory/Critical Care segments have increased by 0.6% for the nine month period ended June 30, 2006 over the comparable period in last fiscal year. The references in this Quarterly Report to international sales adjusted to exclude foreign exchange rates may represent “Non-GAAP Financial Measures”. We believe that these references are helpful in describing the underlying operations of the Company.

The following are the net revenues by business segment for the nine months ended June 30, 2006 compared to the nine months ended June 30, 2005:


Net revenue by business segment


Nine months ended June 30, (dollars in thousands)	2006		2005		Percent change


Anesthesia	$	72,173	$	65,489	10.2	%
Respiratory/critical care		32,943		31,714	3.9	%
Sleep disorder		33,780		31,862	6.0	%
Pharmaceutical technology services		12,306		12,353	(0.4	)%

Total	$	151,202	$	141,418	6.9	%

Anesthesia. Sales of anesthesia products increased 10.2% from $65.5 million for the nine months ended June 30, 2005 to $72.2 million for the nine months ended June 30, 2006. Domestic sales of anesthesia products increased 10.2% from $59.3 million for the nine months ended June 30, 2005 to $65.3 million for the nine months ended June 30, 2006. International sales of anesthesia products increased 10.4%, from $6.2 million for the nine months ended June 30, 2005 to $6.8 million for the nine months ended June 30, 2006.

Respiratory/critical care. Sales of respiratory/critical care products increased 3.9%, from $31.7 million for the nine months ended June 30, 2005 to $32.9 million for the nine months ended June 30, 2006, resulting primarily from increases in sales of our respirator product line our blood pressure cuff product lines, offset in part by declines in our ABG product line. Domestic sales of respiratory/critical care products increased by 8.3%, from $21.4 million for the nine months ended June 30, 2005 to $23.2 million for the nine months ended June 30, 2006. International sales of respiratory/critical care products decreased by 5.2%, from $10.3 million for the nine months ended June 30, 2005 to $9.7 million for the nine months ended June 30, 2006.

Sleep Disorder. Net revenues in our sleep disorder segment increased 6.0% (an increase of 11.9% excluding foreign exchange) from $31.9 million for the nine months ended June 30, 2005 to $33.8 million for the nine months ended June 30, 2006. Revenues for Breas, our European manufacturer of personal ventilators and CPAP devices, decreased 2.7%, from $19.7 million during the nine months ended June 30, 2005 to $19.2 million during the nine months ended June 30, 2006. Offsetting the unfavorable effect of foreign exchange of approximately $1.7 million, were increased ventilator revenues from the sales of Breas’ new Vivo product line. The net revenues at Sleep Services of America (SSA), our domestic sleep disorder diagnostic business, increased 20.2%, resulting from growth in diagnostic revenues derived from increased utilization at existing labs and an increase in study rates. Same center revenue growth was 21%

Pharmaceutical technology services. Service revenues in our pharmaceutical technology services segment for the nine months ended June 30, 2006 decreased by 0.4% from $12.4 million for the nine months ended June 30, 2005 to $12.3 million for the nine months ended June 30, 2006.

Gross profit

We have set forth below the dollar amount of our gross profits and our gross profit margins for each of our four segments:



Nine months ended June 30, (Dollars in thousands)	2006					2005

	Gross profit		Gross profit margin			Gross profit		Gross profit margin
Anesthesia	$	37,390		51.8	%	$	35,242		53.8	%
Respiratory/critical care		17,328		52.6			16,808		53.0
Sleep disorder		18,214		53.9			14,698		46.1
Pharmaceutical technology services		4,299		34.9			4,647		37.6

Total	$	77,231		51.1	%	$	71,395		50.5	%

The gross profit dollar improvements in our anesthesia and respiratory/critical care segments result primarily from the sales volume increases described above. These increases were offset by increased costs for plastic resins and inbound freight resulting from higher oil costs experienced nationwide. The gross profit margin in the anesthesia and respiratory/critical care segments declined as a result of the increased costs described previously.

The gross profit dollar increase in our sleep disorder segment resulted from improved utilization at our sleep diagnostic centers as well a higher gross profit margin on new Breas products. The gross profit margin in sleep disorder diagnostic services increased from 52.4% for the nine months ended June 30, 2005 to 58.5% for the nine months ended June 30, 2006 resulting primarily from revenue growth while maintaining costs at historical levels. The gross profit margin at Breas increased from 42.2% for the nine months ended June 30, 2005 to 50.4% for the nine months ended June 30, 2006 reflecting the sale of the new Breas products at a higher profit margin.

The gross profit dollar decline and gross profit margin decline in our pharmaceutical technology services segment during the nine months ended June 30, 2006 compared to the nine months ended June 30, 2005.

Operating Expenses

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased 4.5%, from $37.8 million for the nine months ended June 30, 2005 to $39.5 million for the nine months ended June 30, 2006.

The increase consists primarily of increased freight expense of $1.5 million relating to our sales volume increase and the fuel surcharges imposed by freight carriers $835,000 for non-cash option compensation expense resulting from the implementation of FASB 123R and increased legal fees of $332,000. and accounting fees of $135,000.These increases were partially offset by foreign exchange of $653,000 and savings of $267,000 in health insurance costs. For information regarding our implementation of FASB 123R, see Note 6 of Notes to Consolidated Financial Statements.

Research and Development Expenses. Research and development expenses decreased by approximately $300,000, or 5.3%, from $5.6 million for the nine months ended June 30, 2005 to $5.3 million for the nine months ended June 30, 2006. The decrease primarily reflects reduced spending at Breas, where the research and development efforts in designing the new family of CPAP and ventilation equipment have been substantially completed.

Restructuring Charge. Restructuring expense for the nine months ended June 30, 2005 consisted of $224,000 of costs related to the final shutdown of our California manufacturing plant which occurred in February 2005.

Other (Income) Expense—Net. Other expense, net, included in operating expenses consisted of $149,000 of net expense for the nine months ended June 30, 2006 and $159,000 of net gain for the nine months ended June 30, 2005. The net expense for the nine months ended June 30, 2006 consisted primarily of severance and donation expense. The net gain for the nine months ended June 30, 2005 consisted primarily of a settlement agreement, realized foreign exchange gains at our Breas subsidiary and the gain on the sale of certain fixed assets.

Interest Income and Expense. Interest income increased $0.8 million from $1.2 million for the nine months ended June 30, 2005 to $2.0 million during the nine months ended June 30, 2006, resulting from the increase in available cash and cash equivalents attributable in part to our February 2006 public offering and increased interest rates.

Provision for Income Taxes. The provision for income tax expense for the nine months ended June 30, 2006 and 2005 was $11.6 million and $10.2 million, respectively, reflecting effective tax rates of 33.8% and 35.1% for these periods, respectively. The 2006 tax rate reflected our ability to utilize a tax deduction available to United States manufacturers resulting from the American Jobs Creation Act of 2005 and the utilization of a tax advantaged investment portfolio to minimize tax on interest income.

Discontinued Operations. The net gain from discontinued operations was $41,000 (consisting of interest income generated from a note receivable) and $95,000 for the nine months ended June 30, 2006 and 2005.

Liquidity and Capital Resources

We believe that the funds generated from operations, along with our current working capital position, will be sufficient to satisfy our capital requirements for at least the next twelve months. Our working capital increased by $18,575,000 as a result of the public offering of 434,000 shares of our common stock during the second quarter of 2006.

Cash flows

Historically, our primary liquidity requirements have been to finance business acquisitions and to support operations. We have funded these requirements primarily through internally generated cash flow.

During the nine months ended June 30, 2006, operating activities provided $21.9 million of net cash. Investing activities used $6.9 million of net cash, consisting of $2.3 million for the purchase of rights related to CO2 indicator technology from Futall AB and $4.6 million for capital additions. Financing activities provided $21.5 million of net cash, consisting of $18.6 million from the public offering of common stock, $4.1 million received from the exercise of stock options and $2.0 million from the tax benefits realized on stock options, offset in part by $3.0 million paid for dividends and $0.2 million for the repurchase of common stock. On May 3, 2006, the Company increased its quarterly dividend from $.07per share to $.09 per share.

During the nine months ended June 30, 2005 operating activities provided $25.2 million net cash. Investing activities used $13.9 million, including the $10 million acquisition of the Baxter disposable airway management product line and capital additions of $3.9 million. Financing activities used $7.4 million, consisting of $7.9 million for the repurchase of common stock, and $2.5 million paid for dividends, which were offset by $3.0 million of cash received from the exercise of stock options.

Cash and working capital

Cash and cash equivalents were $119.3 million at June 30, 2006 as compared to $81.8 million at September 30, 2005. At June 30, 2006, our working capital was $162.4 million compared to $119.6 million at September 30, 2005. At June 30, 2006, the current ratio was 12.1 to 1.0 and at September 30, 2005 the current ratio was 7.9 to 1.0.

Debt

We have no committed lines of financing.

Working capital policy and capital expenditures

Our current policy is to retain working capital and earnings for use in our business, subject to the payment of certain cash dividends. Such funds may be used for the buyback of our common stock, business acquisitions, product acquisitions and product development, among other things. We regularly evaluate and negotiate with domestic and foreign medical device companies regarding potential business or product line acquisitions, licensing arrangements and strategic alliances.

Capital expenditures for the first nine months of fiscal 2006 were approximately $4.7 million, and primarily included expenditures for the capitalized cost of software development ($0.4 million); the purchase of building improvements at our Totowa, NJ plant ($0.6 million); new extrusion equipment and molds at our Totowa, NJ plant ($0.9 million); upgrades to our MIS systems at our Totowa headquarters and Colorado plant ($1.0 million) molds and equipment used at our Colorado manufacturing plant ($0.5 million); equipment at our Thomas Medical Product subsidiary ($0.5 million); patents and trademarks ($0.2 million); tools and equipment at our Breas facility ($0.3 million) and other capital additions at Sleep Services of America subsidiaries. We expect that our total capital expenditures for fiscal 2006 will increase slightly above our total capital spending of $5.6 million in fiscal 2005. This statement represents a forward-looking statement under the Exchange Act and the Securities Act. Actual results could differ materially from this statement for a number of reasons, including the possibility that we may determine that our business requires new equipment in order to meet competitive and/or technological challenges.

Other

At June 30, 2006 and 2005, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We do not have material relationships or transactions with persons or entities that derive benefits from their non-independent relationship with us or our related parties other than what is disclosed in our Annual Report on Form 10-K for the year ended September 30, 2005.

On August 2, 2006, our Board of Directors approved a quarterly dividend of $0.09 per share payable on August 31, 2006 to shareholders of record at the close of business on August 24, 2006.

Critical accounting estimates

The preparation of our consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended September 30, 2005 for a discussion of the estimates and judgments necessary in our accounting for revenue recognition, allowances for rebates and doubtful accounts, allowances for inventory, valuation of long-lived and intangible assets and legal contingencies.

Stock Option Compensation

Effective October 1, 2005, we began recording compensation expense associated with stock options in accordance with SFAS No. 123R, “Share-Based Payment”. Prior to October 1, 2005, we accounted for stock-based compensation related to stock options under the recognition and measurement principles of Accounting Principles Board Opinion No. 25; therefore, we measured compensation expense for our stock option plans using the intrinsic value method, that is, as the excess, if any, of the fair market value of our stock at the grant date over the amount required to be paid to acquire the stock, and provided the disclosures required by SFAS Nos. 123 and 148. We have adopted the modified prospective transition method provided under SFAS No. 123R, and as a result, have not retroactively adjusted results from prior periods. Under this transition method, compensation expense associated with stock options recognized in the first and second quarters of fiscal year 2006 includes: (1) expense related to the remaining unvested portion of all stock option awards granted prior to October 1, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123; and (2) expense related to any stock option awards granted subsequent to October 1, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123R.

As a result of the adoption of SFAS No. 123R, our net income for the three month and nine month periods ended June 30, 2006 includes $329,000 and $1,093,000, respectively, of compensation expense and $114,000 and $370,000, respectively, of income tax benefits related to our stock options. The compensation expense related to all of our stock-based compensation arrangements is recorded as a component of both selling, general and administrative and research and development expenses. Prior to our adoption of SFAS No. 123R, we presented tax benefits resulting from the exercise of stock options as cash flows from operating activities on our consolidated statements of cash flows. SFAS No. 123R requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities.

Recent accounting pronouncements

In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109 (“FIN 48”), which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions. A tax benefit from an uncertain position may be recognized only if it is “more likely than not” that the position is sustainable based on its technical merits. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. We do not expect FIN 48 will have a material effect on our consolidated financial condition or results of operations.

The Company does not believe that any recently issued but not yet effective accounting standards will have a material effect on the Company’s financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks, including the impact of material price changes and changes in the market value of our investments and, to a lesser extent, interest rate changes and foreign currency fluctuations. In the normal course of business, we seek to limit the impact of market risks on earnings and cash flows.

The impact of interest rate changes is not material to our financial condition. We do not enter into interest rate transactions for speculative purposes.

For the first nine months of fiscal 2006, our international net revenue represented approximately 23.7% of our total net revenues. Our Breas subsidiary, located in Sweden, represented 53.6% of our total international net revenues during the first nine months of fiscal 2006. We do not enter into any derivative transactions, including foreign currency transactions, for speculative purposes. We have not entered into any derivative instrument transactions, such as foreign exchange forward or option contracts, as of June 30, 2006.

Our primary risk involving price changes relates to raw materials used in our operations. We are exposed to changes in the prices of resins and latex for the manufacture of our products. We do not enter into commodity futures or derivative instrument transactions. Except with respect to our single source of supply for facemasks, we seek tomaintain commercial relations with multiple suppliers and when prices for raw materials rise to attempt to source alternative supplies.

Item 4. Controls and Procedures

(a) Disclosure controls and procedures. As of the end of the most recently completed fiscal quarter covered by this report, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in ensuring that information required to be disclosed by Vital Signs in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

(b) Changes in internal controls over financial reporting. There have been no changes in our internal controls over financial reporting that occurred during the last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings:

On December 6, 1999 a complaint was filed against us on behalf of former shareholders of our Vital Pharma subsidiary alleging breach of contract for failure to pay earnout payments allegedly due under the stock purchase agreement executed in connection with our purchase of Vital Pharma in January 1996. In August 2000 the court ordered the plaintiff to submit such claims to binding arbitration and stayed all other proceedings pending the outcome of the arbitration. The arbitration hearing commenced on January 26, 2004. The presentation of testimony of both the plaintiff’s direct case and the defendant’s case has been completed and post-arbitration briefs have been presented. We are currently waiting for the arbitrator to render a decision, which may come at any time. Plaintiffs originally claimed damages in the pre-interest amount of approximately $8.0 million. In plaintiffs’ post-arbitration brief to the arbitrator, plaintiffs argued that the final calculation of their damages could be in excess of $14,000,000. We have recorded a reserve of approximately $600,000 in connection with this proceeding.

We are also involved in other legal proceedings arising in the ordinary course of business. We cannot predict the outcome of our legal proceedings with certainty. However, based upon our review of pending legal proceedings, we do not believe the ultimate disposition of our pending legal proceedings will be material to our financial condition or results of operations. Predictions regarding the impact of pending legal proceedings constitute forward-looking statements. The actual results and impact of such proceedings could differ materially from the impact anticipated, primarily as a result of uncertainties involved in the proof of facts in legal proceedings.

Item 6. Exhibits


Exhibits


31.1	—	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2	—	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	—	Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	—	Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Vital Signs, Inc.

	By:	/s/ William Craig

	William Craig
	Chief Financial Officer

Date: August 3, 2006

EXHIBIT INDEX


Exhibits


31.1		Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.